Specific Cytogenetic Abnormalities Are Associated with a Significantly Inferior Outcome in Children and Adolescents with Mature B-cell Non-Hodgkin's Lymphoma: Results of the FAB/LMB 96 International Study

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2008 Nov 21

PMID 19020548

Citations 39

Authors

H A Poirel

M S Cairo

N A Heerema

J Swansbury

A Auperin

E Launay

W G Sanger

P Talley

S L Perkins

M Raphael

K McCarthy

R Sposto

M Gerrard

A Bernheim

C Patte

Affiliations

Soon will be listed here.

Abstract

Clinical studies showed that advanced stage, high LDH, poor response to reduction therapy and combined bone marrow and central nervous system disease are significantly associated with a decreased event-free survival (EFS) in pediatric mature B-cell non-Hodgkin's lymphoma (B-NHL) treated on FAB/LMB96. Although rearranged MYC/8q24 (R8q24) is characteristic of Burkitt lymphoma (BL), little information is available on other cytogenetic abnormalities and their prognostic importance. We performed an international review of 238 abnormal karyotypes in childhood mature B-NHL treated on FAB/LMB96: 76% BL, 8% Burkitt-like lymphoma, 13% diffuse large B-cell lymphoma (DLBCL). The main BL R8q24-associated chromosomal aberrations were +1q (29%), +7q and del(13q) (14% each). The DLBCL appeared heterogeneous and more complex. Incidence of R8q24 (34%) was higher than reported in adult DLBCL. The prognostic value of cytogenetic abnormalities on EFS was studied by Cox model controlling for the known risk factors: R8q24, +7q and del(13q) were independently associated with a significant inferior EFS (hazard ratio: 6.1 (P=0.030), 2.5 (P=0.015) and 4.0 (P=0.0003), respectively). The adverse prognosis of R8q24 was observed only in DLBCL, whereas del(13q) and +7q had a similar effect in DLBCL and BL. These results emphasize the significant biological heterogeneity and the development of cytogenetic risk-adapted therapy in childhood mature B-NHL.

Citing Articles

binding domain mutations are bad news in Burkitt lymphoma.

Cairo M Haematologica. 2024; 109(9):2775-2777.

PMID: 38634119 PMC: 11367188. DOI: 10.3324/haematol.2024.285213.

Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.

El Dana F, Garces Narvaez S, El-Mallawany N, Agrusa J, Dreyer Z, Marcogliese A Pediatr Dev Pathol. 2024; 27(4):348-353.

PMID: 38468555 PMC: 11340240. DOI: 10.1177/10935266241230600.

Acute Lymphoblastic Leukemia Transformation with a Precursor B-Cell Immunophenotype to Burkitt's Lymphoma: a Case Report.

Jafari M, Ansari Damavandi S, Charmduzi F Caspian J Intern Med. 2023; 14(4):760-764.

PMID: 38024161 PMC: 10646355. DOI: 10.22088/cjim.14.4.760.

EBV and 1q Gains Affect Gene and miRNA Expression in Burkitt Lymphoma.

Akyuz N, Janjetovic S, Ghandili S, Bokemeyer C, Dierlamm J Viruses. 2023; 15(9).

PMID: 37766215 PMC: 10537407. DOI: 10.3390/v15091808.

High-grade B-cell lymphoma with 11q aberrations: A single-center study.

Yamada S, Oka Y, Muramatsu M, Hashimoto Y J Clin Exp Hematop. 2023; 63(2):121-131.

PMID: 37380468 PMC: 10410621. DOI: 10.3960/jslrt.23007.

References

Harris N, Jaffe E, STEIN H, Banks P, Chan J, Cleary M . A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84(5):1361-92. View

Ogden C, Pound J, Batth B, Owens S, Johannessen I, Wood K . Enhanced apoptotic cell clearance capacity and B cell survival factor production by IL-10-activated macrophages: implications for Burkitt's lymphoma. J Immunol. 2005; 174(5):3015-23. DOI: 10.4049/jimmunol.174.5.3015. View

Dave B, Weisenburger D, Higgins C, Pickering D, Hess M, Chan W . Cytogenetics and fluorescence in situ hybridization studies of diffuse large B-cell lymphoma in children and young adults. Cancer Genet Cytogenet. 2004; 153(2):115-21. DOI: 10.1016/j.cancergencyto.2004.01.008. View

Lindstrom M, Wiman K . Role of genetic and epigenetic changes in Burkitt lymphoma. Semin Cancer Biol. 2002; 12(5):381-7. DOI: 10.1016/s1044-579x(02)00058-5. View

Lai J, Fenaux P, Zandecki M, Nelken B, Huart J, DEMINATTI M . Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities. Ann Genet. 1989; 32(1):26-32. View

Wilda M, Bruch J, Harder L, Rawer D, Reiter A, Borkhardt A . Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children. Leukemia. 2004; 18(3):584-8. DOI: 10.1038/sj.leu.2403254. View

Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker H, Burkhardt B . Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial. Blood. 2006; 107(10):4047-52. DOI: 10.1182/blood-2005-10-4213. View

Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth T . A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006; 354(23):2419-30. DOI: 10.1056/NEJMoa055351. View

Garcia J, Hernandez J, Gutierrez N, Flores T, Gonzalez D, Calasanz M . Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study. Leukemia. 2003; 17(10):2016-24. DOI: 10.1038/sj.leu.2403080. View

10.

Johansson B, Mertens F, Mitelman F . Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood. 1995; 86(10):3905-14. View

11.

Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D . The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001; 97(11):3370-9. DOI: 10.1182/blood.v97.11.3370. View

12.

Heerema N, Bernheim A, Lim M, Look A, Pasqualucci L, Raetz E . State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: summary report of workshop at the First International Symposium on childhood and adolescent non-Hodgkin lymphoma, April 9, 2003, New York City, NY. Pediatr Blood Cancer. 2005; 45(5):616-22. DOI: 10.1002/pbc.20552. View

13.

Berger R, Bernheim A . Cytogenetics of Burkitt's lymphoma-leukaemia: a review. IARC Sci Publ. 1985; (60):65-80. View

14.

Calin G, Liu C, Sevignani C, Ferracin M, Felli N, Dumitru C . MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004; 101(32):11755-60. PMC: 511048. DOI: 10.1073/pnas.0404432101. View

15.

Rosenwald A, Wright G, Chan W, Connors J, Campo E, Fisher R . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346(25):1937-47. DOI: 10.1056/NEJMoa012914. View

16.

Gerrard M, Cairo M, Weston C, Auperin A, Pinkerton R, Lambilliote A . Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol. 2008; 141(6):840-7. DOI: 10.1111/j.1365-2141.2008.07144.x. View

17.

Battey J, Moulding C, TAUB R, Murphy W, Stewart T, Potter H . The human c-myc oncogene: structural consequences of translocation into the IgH locus in Burkitt lymphoma. Cell. 1983; 34(3):779-87. DOI: 10.1016/0092-8674(83)90534-2. View

18.

Lones M, Sanger W, Le Beau M, Heerema N, Sposto R, Perkins S . Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08. J Pediatr Hematol Oncol. 2004; 26(3):169-78. DOI: 10.1097/00043426-200403000-00006. View

19.

Berger R, Le Coniat M, Derre J, Vecchione D . Secondary nonrandom chromosomal abnormalities of band 13q34 in Burkitt lymphoma-leukemia. Genes Chromosomes Cancer. 1989; 1(2):115-8. DOI: 10.1002/gcc.2870010202. View

20.

Knutsen T . Cytogenetic changes in the progression of lymphoma. Leuk Lymphoma. 1998; 31(1-2):1-19. DOI: 10.3109/10428199809057581. View